Q32 Bio Q2 net loss $8.9M; positive bempikibart Phase 2a data; $200M offering

Q32 Bio Inc.

Net loss $8.9M ($0.44/share) vs $9.5M ($0.78) in Q2 2025; R&D expense $4.3M, G&A $4.9M.
Cash $106.3M at June 30, 2026; combined with $200M July offering funds through Phase 3 topline.
Bempikibart showed 35.3% mean SALT reduction at Week 36; 40% SALT-20 response (mITT) in SIGNAL-AA Part B.
Registration-directed program for severe/very severe AA expected to start 1H2027, pending regulatory discussions.
ADX-914-XL (half-life extended anti-IL-7Rα) advancing in preclinical development.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.